Ligand Pharmaceuticals has entered into a definitive agreement to acquire development and licencing biotechnology firm Pfenex in a deal valued at approximately $516m.
Kolon Life Sciences dosed the first patient in a Phase III trial for Invossa this month. It is hoping to be granted the US Food and Drug Administration’s (FDA) Disease Modifying Osteoarthritis Drug (DMOAD) label.